Skip to main content
. 2019 Feb 15;10(14):1440–1457. doi: 10.18632/oncotarget.26677

Figure 1. The occurrence of RASGAP and oncogenic mutations in the MAPK signaling pathway in lung adenocarcinoma, melanoma and colorectal adenocarcinoma.

Figure 1

The distribution of driver mutations and copy number alterations in KRAS, NRAS, HRAS, BRAF, and RASGAPs in (A) lung adenocarcinoma (n = 230), (B) skin cutaneous melanoma (n = 287) and (C) colorectal adenocarcinoma (n = 212) from TCGA datasets are shown. Data were extracted through cBioPortal and presented as OncoPrint. Color coding indicates mutation type: red, homozygous amplification; blue, homozygous deletion; green, missense mutation; brown, inframe putative driver mutation; black, truncating mutation. Left, mutation percentage.